trending Market Intelligence /marketintelligence/en/news-insights/trending/dyIFzz8lsD0WkSSIVKIPvw2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Merrimack stockholders back oncology assets sale to Ipsen

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Merrimack stockholders back oncology assets sale to Ipsen

Merrimack Pharmaceuticals Inc.'s stockholders, at a March 30 special meeting, approved the sale of oncology assets to Ipsen SA.

The company will give Ipsen its commercialized pancreatic cancer product, Onivyde, including U.S. commercialization rights and its licensing agreements with Shire PLC.

In addition, the deal covers Merrimack's generic doxorubicin hydrochloride liposome injection, Doxil, which is advanced under a development, license and supply agreement with Actavis LLC.

Merrimack expects the transaction to be completed in the coming days.